IL-6 is highly expressed in fibroblasts during the early stage of RA (Filer et al., 2017) and its inhibitor has started being used for clinical treatment (McInnes and Schett, 2017), as well as TNF-α. Here, IL6 is linked to rheumatoid arthritis.